Eli Lilly's stock has underperformed the broader market in 2026 despite a strong 5-year run, trading at 40x earnings. Wall Street analysts are modestly bullish with an average price target of $1,325 (11% upside), with 25 of 30 analysts recommending buy. The expanding GLP-1 market, projected to reach $190 billion by...
Eli Lilly discontinued development of a new GLP-1 weight-loss drug that failed to meet efficacy expectations. While GLP-1 drugs (Mounjaro, Zepbound, Foundayo) account for over 65% of the company's revenue, Eli Lilly is strategically preparing for future patent expirations by aggressively investing in its drug pipeline...
Viking Therapeutics released positive maintenance dosing data for its GLP-1 drug candidate VK2735, causing the stock to surge 35%. The company is positioning itself as a potential competitor in the $100 billion weight loss drug market dominated by Eli Lilly and Novo Nordisk. Viking's dual GLP-1/GIP agonist could be the...
The global autoimmune disease therapeutics market is projected to grow from USD 133 billion in 2025 to USD 255 billion by 2034, with an 8% CAGR. Growth is driven by rising prevalence of autoimmune disorders, increasing adoption of biologics and targeted therapies, advancements in precision medicine, and expanding...
InnoCare Pharma has entered into a strategic research collaboration and license agreement with Eli Lilly to discover and develop compounds against up to five targets. Under the agreement, InnoCare is eligible to receive up to $100 million in upfront and near-term payments, plus up to $3.25 billion in development and...
HUTCHMED announced that two Phase III studies evaluating the savolitinib and osimertinib combination for non-small cell lung cancer will be presented at ESMO Congress 2026 in Madrid. The SAFFRON global study and SANOVO China study both demonstrated statistically significant and clinically meaningful improvements in...
Novo Nordisk received positive regulatory recommendations in Europe for Frehemgo (hemophilia A treatment) and Sogroya (growth hormone therapy for multiple indications), potentially diversifying revenue beyond its pressured GLP-1 portfolio. However, the company faces intensifying competition from Eli Lilly's blockbuster...
A $1,000 investment in Halozyme Therapeutics made in September 2016 would be worth $9,284.68 as of September 23, 2026, representing an 828.47% gain. The biopharmaceutical company's growth is driven by royalties from its ENHANZE drug delivery technology licensed to major pharma partners. However, biosimilar competition...
Viking Therapeutics' stock surged 35.67% after announcing positive clinical trial results for its obesity drug VK2735. Participants lost 16-19% of body weight over 21 weeks and maintained up to 97% of weight loss with flexible dosing schedules. The drug showed strong tolerability with low discontinuation rates,...
The Invesco Nasdaq Biotechnology ETF (IBBQ) offers lower costs (0.19% expense ratio) and higher 1-year returns (44.6%), making it suitable for growth-focused investors willing to accept volatility. The iShares U.S. Healthcare ETF (IYH) provides broader diversification across 100 healthcare holdings with higher dividend...
Novo Nordisk is rebranding to 'Novo' as it launches a pill version of its GLP-1 weight-loss drug to regain market share lost to Eli Lilly. While the company has a solid strategy with low pricing to drive volume, the name change alone won't address fundamental competitive challenges. The stock is down 70% from its 2024...
Roche reported positive Phase II results for enicepatide, its once-weekly dual GLP-1/GIP receptor agonist, showing dose-dependent HbA1c reductions of 2.65% and body weight loss of 15.5% at the 24 mg dose in type 2 diabetes patients. The drug was well-tolerated with minimal discontinuations. Roche is advancing two Phase...
The article compares two dividend investment strategies: Eli Lilly offers modest 0.6% yield but exceptional 15.3% annual dividend growth rate and strong growth prospects in the GLP-1 market, while Pfizer provides a high 6.2% yield with sustainable dividends backed by $11 billion in free cash flow. The choice depends on...
Eli Lilly closed at $1,164.89, up 1.04% but underperforming the S&P 500's 1.49% gain. The stock declined 8.16% over the past month, trailing the broader market. Analysts expect strong earnings growth of 36.18% YoY with revenue projected at $22.08 billion (+25.46%), but the company trades at a premium valuation with a...
Twist Bioscience stock surged over 31% this week after announcing a partnership with Eli Lilly to participate in Lilly TuneLab, an AI-powered drug discovery initiative. Twist will provide antibody characterization data services and leverage its AbLab model, generating revenue while contributing to and benefiting from...
Biotech M&A activity has accelerated sharply in 2026, with deal value reaching $130 billion in H1 alone. Four biotech companies—Abivax, Iovance Biotherapeutics, Viking Therapeutics, and BioCryst Pharmaceuticals—are highlighted as potential acquisition targets due to their differentiated late-stage assets and strategic...
The article compares Eli Lilly and Costco as defensive stock picks for cautious investors amid market hesitation. Eli Lilly benefits from its dominant GLP-1 weight loss drug portfolio (Mounjaro and Zepbound), while Costco offers stability through its membership-based business model with high renewal rates. Despite both...
AstraZeneca's stock has declined following several late-stage pipeline failures including Wainua in ATTR-CM, Ultomiris in HSCT-TMA, volrustomig in NSCLC, and Etcamah in breast cancer. However, the company maintains a broad pipeline with over 20 expected high-value readouts in the next 18 months, particularly in...
Johnson & Johnson's stock has risen 18.3% in three months, driven by strong Innovative Medicine segment growth (6.2% organic), successful new drug launches (Icotyde, Imaavy, Inlexzo), and progress on talc litigation resolution. The company targets $100 billion in 2026 revenues and expects double-digit growth excluding...
Eli Lilly's GLP-1 franchise, led by Mounjaro and Zepbound, generated $27.7 billion in first-half 2026 sales and continues driving growth. The company's oral obesity pill Foundayo shows encouraging uptake with coverage across major PBMs, while newer therapies grew 121% in Q2, diversifying revenue beyond GLP-1. However,...
Headlines via Polygon.io. Links open the original publisher.